{"id":11672,"date":"2025-03-18T15:36:44","date_gmt":"2025-03-18T15:36:44","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=11672"},"modified":"2025-03-18T15:53:31","modified_gmt":"2025-03-18T15:53:31","slug":"kactus-dna-synthesis-enzymes","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/kactus-dna-synthesis-enzymes\/","title":{"rendered":"KACTUS: DNA Synthesis Enzymes"},"content":{"rendered":"\n

Background<\/h2>\n\n\n\n

In recent years, the field of cell and gene therapy has made rapid progress. It is reported that there are over 300 clinical projects based on AAV vectors worldwide, generally produced through triple plasmid co-transfection. Additionally, there are nearly 1,000 CAR-T clinical trials underway, most of which transduce CAR constructs using lentiviral vectors produced through transient transfection using four plasmids. Consequently, the demand for plasmids in the market is also continuously increasing.<\/p>\n\n\n\n

Traditional plasmid production involves the fermentation of E. coli, which poses several challenges in commercial production. For instance, plasmids contain extraneous sequences, such as antibiotic resistance genes and origins of replication, which can affect plasmid yield. The entire process, which includes fermentation, extraction, purification, and quality control, is time-consuming and costly. Moreover, there is a risk of genetic recombination between E. coli and plasmid DNA, leading to safety incidents.<\/p>\n\n\n\n

In vitro enzymatic synthesis of DNA vectors can effectively replace traditional plasmid DNA production, perfectly avoiding the many uncontrollable risks of biological fermentation. The production process is simpler and more controllable, allowing for commercial production in a shorter time frame and having broad applications in the field of cell and gene therapy.<\/p>\n\n\n\n

KACTUS has developed a series of off-the-shelf, high-activity enzyme for in vitro synthesis of DNA vectors, based on their functional recombinant protein and enzyme technology platform, SAMS\u2122<\/a>.<\/p>\n\n\n\n

Product Features & Performance<\/h2>\n\n\n\n

TelN Protelomerase<\/h3>\n\n\n\n

TelN protelomerase cleaves dsDNA at its recognition site and leaves covalently closed ends. It can be used for DNA vaccine development as well as for non-viral therapy vectors. TelN Protelomerase is isolated from phage N15.<\/p>\n\n\n\n

\"\"
Figure 1. TelN Protelomerase efficiently converts plasmid DNA into linear DNA with hairpin ends. In this figure, TelN Protelomerase cut substrate DNA containing 513 fmol cleaveage site, followed by agarose gel analysis.<\/figcaption><\/figure>\n\n\n\n
\n
TelN Protelomerase<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/a>Phi29 DNA Polymerase<\/h3>\n\n\n\n

Phi29 DNA polymerase is a highly processive enzyme that can efficiently amplify DNA sequences in vitro<\/em>. It is often used as an alternative to the more commonly used polymerase chain reaction (PCR) method for DNA amplification. Phi29 DNA polymerase amplification has several advantages over PCR, including higher processivity, reduced reaction time, and higher fidelity. It is particularly useful for amplifying DNA from samples with limited starting material, such as ancient DNA or single cells. It is a highly robust enzyme and is suitable for rolling circle amplification (RCA), multiple-displacement amplification (MDA), and whole genome amplification.<\/p>\n\n\n\n

\"\"
Figure 2. Rolling cycle amplification of pUC57 plasmid with phi29 DNA Polymerase. Product was digested with BspQI and then analysed with Agarose gel.<\/figcaption><\/figure>\n\n\n\n
\n
Phi29 DNA Polymerase<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/a>Exonuclease III<\/h3>\n\n\n\n

Exonuclease III is a highly processive enzyme that hydrolyses the phosphodiester bonds in DNA in the 3′ to 5′ direction, resulting in stepwise removal of nucleotides. Exonuclease III catalyses the removal of nucleotides from linear or nicked double stranded DNA. Degradation of Exonuclease III could be initiated from a 3\u2019 blunt end, 3\u2019 recessed end, 3\u2019 overhangs with less than 4 bases and nicked DNA.<\/p>\n\n\n\n

\"\"
Figure 3. Digestion of 1\u03bcg linearised plasmid using Exonuclease III, followed by Agarose gel analysis.<\/figcaption><\/figure>\n\n\n\n
\n
Exonuclease III<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/a>Restriction Endonucleases<\/h3>\n\n\n\n

There are two types of DNA vectors formed by TelN Protelomerase cutting and ligation, one containing the backbone sequence and the other containing the target fragment. There are corresponding restriction enzyme sites on the backbone sequence. KACTUS provides highly active restriction endonucleases for digestion of the backbone sequence.<\/p>\n\n\n\n

Enzyme<\/th>Cut Site<\/th><\/tr><\/thead>
BsaI<\/a><\/td>5’…GGTCTC(N)1 \u2193 …3′
3’…CCAGAG(N)5 \u2191 …5′<\/td><\/tr>
BspQI<\/a><\/td>5’…GCTCTTC(N)1 \u2193 …3′
3’…CGAGAAG(N)4 \u2191 …5′<\/td><\/tr>
KpnI<\/a><\/td>5’…GGTAC \u2193 C…3′
3’…C \u2191 CATGG…5′<\/td><\/tr>
NruI<\/a><\/td>5’…TCG \u2193 CGA…3′
3’…AGC \u2191 GCT…5′<\/td><\/tr>
SalI<\/a><\/td>5’…G \u2193 TCGAC…3′
3’…CAGCT \u2191 G…5′<\/td><\/tr>
SapI<\/a><\/td>5’…GCTCTTC(N)1 \u2193 …3′
3’…CGAGAAG(N)4 \u2191 …5′<\/td><\/tr>
XbaI<\/a><\/td>5’…T \u2193 CTAGA…3′
3’…AGATC \u2191 T…5′<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Applications<\/h2>\n\n\n\n